Myocardial infarction is myocardial necrosis caused by acute and persistent ischemia and hypoxia of coronary artery, with high incidence rate and mortality. Although the recovery of blood supply through coronary intervention or thrombolytic drugs can improve the survival rate of patients, it is difficult to rescue the lost cardiomyocytes in the infarcted area, and the limited self repair ability of the adult mammalian heart is the main factor that causes myocardial fibrosis and eventually progresses to heart failure. For a long time, the existing treatment methods are difficult to reverse the process of heart failure after myocardial infarction. Cell transplantation is a promising therapeutic method to promote the repair and regeneration of infarcts. Due to the ischemia and hypoxia microenvironment, the limited survival and retention of stem cells after transplantation are not ideal. And acellular biomaterials promoting angiogenesis and reducing fibrosis show the potential of preclinical treatment. This paper summarizes the advantages and disadvantages of various acellular biomaterials, epicardial infarct repair and intramyocardial injection in a minimally invasive manner to promote cardiac regeneration and improve cardiac function, and to promote myocardial regeneration by combining acellular biomaterials with optimized drugs in the future for reference.